In a new interview with Biostock, Chordate’s CEO Anders Weilandt discusses the rights issue intended to finance ongoing value creation ahead of a potential exit. The proceeds from the issuance will be used, among other things, to establish proof-of-concept in selected markets for the migraine and rhinitis treatment Ozilia.
“We see how the project as a whole has attained a significantly lower risk level due to the highly favorable study results. In the second half of 2023, we observed the fruition of our market efforts. Chordate as an investment should be considered to have transitioned from a technical/scientific development project to a phase of market validation. Investors, of course, have different perspectives, but I assess that this clear shift in risk level should attract investors with experience in life science investments,” says Anders Weilandt to Biostock.
Read the full interview (In Swedish)